These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 9179871)

  • 1. Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs.
    Dickinson T; Fleetwood-Walker SM; Mitchell R; Lutz EM
    Neuropeptides; 1997 Apr; 31(2):175-85. PubMed ID: 9179871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
    Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
    Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
    Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret MC; Rathe J; De Neef P; Waelbroeck M; Robberecht P
    Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct receptors mediate pituitary adenylate cyclase-activating peptide- and vasoactive intestinal peptide-induced relaxation of rat ileal longitudinal muscle.
    Ekblad E; Sundler F
    Eur J Pharmacol; 1997 Sep; 334(1):61-6. PubMed ID: 9346329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
    Jiang X; Wang HY; Yu J; Ganea D
    Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
    Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
    Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
    Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
    Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland.
    Vertongen P; Delhase M; Rajas F; Trouillas J; Hooghe-Peters E; Svoboda M; Robberecht P
    J Mol Endocrinol; 1996 Jun; 16(3):239-48. PubMed ID: 8782082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
    Van Rampelbergh J; Poloczek P; Françoys I; Delporte C; Winand J; Robberecht P; Waelbroeck M
    Biochim Biophys Acta; 1997 Jun; 1357(2):249-55. PubMed ID: 9223629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of mRNAs for pituitary adenylate cyclase-activating polypeptide (PACAP), PACAP receptor, vasoactive intestinal polypeptide (VIP), and VIP receptors in the rat superior cervical ganglion.
    Nogi H; Hashimoto H; Hagihara N; Shimada S; Yamamoto K; Matsuda T; Tohyama M; Baba A
    Neurosci Lett; 1997 May; 227(1):37-40. PubMed ID: 9178853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facilitatory effects of pituitary adenylate cyclase activating polypeptide (PACAP) on neurons in the magnocellular portion of the rat hypothalamic paraventricular nucleus (PVN) in vitro.
    Uchimura D; Katafuchi T; Hori T; Yanaihara N
    J Neuroendocrinol; 1996 Feb; 8(2):137-43. PubMed ID: 8868261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
    Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy.
    Dickinson T; Mitchell R; Robberecht P; Fleetwood-Walker SM
    Neuropharmacology; 1999 Jan; 38(1):167-80. PubMed ID: 10193908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion.
    Inagaki N; Kuromi H; Seino S
    Ann N Y Acad Sci; 1996 Dec; 805():44-51; discussion 52-3. PubMed ID: 8993392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasoactive intestinal polypeptide- and pituitary adenylate cyclase activating polypeptide-mediated control of catecholamine release from chromaffin tissue in the rainbow trout, Oncorhynchus mykiss.
    Montpetit CJ; Perry SF
    J Endocrinol; 2000 Sep; 166(3):705-14. PubMed ID: 10974664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
    Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
    Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor.
    Uchida D; Tatsuno I; Tanaka T; Hirai A; Saito Y; Moro O; Tajima M
    Ann N Y Acad Sci; 1998 Dec; 865():253-8. PubMed ID: 9928019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.